NEW MODE OF PROLONGED HORMONAL CONTRACEPTION
https://doi.org/10.21518/2079-701X-2017-13-38-42
Abstract
Hormonal contraception continues to be one of the most effective methods of protection against unwanted pregnancies. Many research trials are aimed at improving of various methods of hormonal contraception, which in turn allows couples to plan for pregnancy. Combined oral contraception is one of the most common methods to prevent unwanted pregnancies worldwide. To date hormonal contraceptives differ between the way they are introduced into the body, the mode of indication, the expression of gestagenic influence, the presence or absence of androgenic, antiandrogenic, antimineralocorticoid, glucocorticoid and other activity.
About the Authors
A. N. Mheryan
Kulakov Scientific Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine,
Moscow
P. R. Abakarova
Kulakov Scientific Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine,
Moscow
E. R. Dovlethanova
Kulakov Scientific Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine,
Moscow
E. A. Mezhevitinova
Kulakov Scientific Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD,
Moscow
References
1. Volumetric concept test, Ipsos, 2014.
2. Market research of COCs market potential. GFK, 2012.
3. Dickey RP, Dorr CH II. Oral contraceptives: selection of the proper pill. Obstet Gynecol, 1969, 33(2): 273–287.
4. Krishnan S. , Kiley J. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 µg/levonorgestrel 100 µg + ethinyl estradiol 10 µg. International Journal of Women’s Health, 2010, 2: 235-239.
5. Vandevera MA, Kuehla TJ, Sulaka PJ et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception, 2008, 77: 162–170.
6. Fenton C et al. Drospirenone/ Ethinylestradiol 3mg/20 g (24/4 Day Regimen): A Review of Its Use in Contraception, Premenstrual Dysphoric Disorder and Moderate Acne Vulgaris. Drugs, 2007, 67(12): 1749-65.
7. Lopez LM et al. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012: CD006586.
8. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gyneco, 1993, 81(6): 1034–1047.
9. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs .20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception, 2005, 71(3): 162–169.
10. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol, 2007, 50(4): 868–877.
11. Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag, 2008, 4(5): 905–911.
12. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril, 1999, 72(1): 115– 120.
13. Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag, 2008, 4(5): 905–911.
14. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception, 2006, 74: 100– 3.
15. Schlaff WD, Lynch AM, Hughes HD, Cedars MI, Smith DL. Manipulation of the pill-free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol, 2004, 190: 943–51.
16. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol, 2000, 95: 261–6.
17. Coffee A, Kuehl TK, Willis SA, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol, 2006, 195: 1311–9.
18. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception, 2006, 74(5): 359–366.
19. Andrist LC, Arias RD, Nucatola D et al. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception, 2004, 70(5): 359–363.
20. Seasonale (levonorgestrel/ethinyl estradiol tablets). Current US Prescribing Information. Duramed Pharmaceuticals.
21. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception, 2006, 73(3): 229–234.
22. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of steroid contraceptives in women. In EMEA/CPMP/EWP/519/98 Rev 1, 2005.
23. Bonnema RA and Spencer AL. The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives. Reproductive Health, 2011, 5: 49–54.
24. Lidegaard O, Nielsen LH, Skovlund CW, et al. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ, 2012, 344: e2990.
25. Burkman R et al. Contraception. 2011;84:19-34.
26. Dhont M. Eur J Contracept Reprod Health Care.
27. Инструкция по применению лекарственного препарата для медицинского применения МОДЭЛЛЬ ЛИБЕРА.
28. LoSeasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets). Current US Prescribing Information. Cincinnati, OH: Duramed Pharmaceuticals.
29. Speroff L, Darney PD. A Clinical Guide for Contraception. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.
30. Trussell J. Contraceptive failure in the United States. Contraception, 2011 May, 83(5): 397-404. 2010; 15(suppl 2): S12–S18
Review
For citations:
Mheryan AN, Abakarova PR, Dovlethanova ER, Mezhevitinova EA. NEW MODE OF PROLONGED HORMONAL CONTRACEPTION. Meditsinskiy sovet = Medical Council. 2017;(13):38-42. (In Russ.) https://doi.org/10.21518/2079-701X-2017-13-38-42
Views:
581
Email this article 